BIOCOPY: the new biomolecule copying and screening solution for diagnostics and therapeutics

Project Information

BIOCOPY

Grant agreement ID: 816576

DOI

10.3030/816576

Project closed

EC signature date 31 May 2018

Start date 1 June 2018

End date 30 September 2018

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

BIOCOPY GMBH
Germany

Periodic Reporting for period 1 - BIOCOPY (BIOCOPY: the new biomolecule copying and screening solution for diagnostics and therapeutics)

Reporting period: 2018-06-01 to 2018-09-30

Summary of the context and overall objectives of the project

Biotechnology and molecular biology have helped to develop therapeutics and diagnostics products, and vaccines have been particularly relevant in human and animal health. However, their discovery and obtention take long times and have high costs, in part because of the inefficient selection and analysis of biomolecules. BioCopy is a German start-up with the goal of provide a unique patented technology for the copying and screening of biomolecules, which is analogous to a photocopier. We have developed a method to copy DNA into DNA/RNA or proteins and we offer as by-products our surfaces, a label-free analytics system and the copying of aptamers and phage/ribosome pools, but we want to focus in the identification of candidate proteins for the development of animal vaccines. We have preliminary developed and validated out technology and now we aim to technically optimize it and validate its use in veterinary vaccines discovery to enter the market successfully.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

At the technical level, we worked on defining the main needs to optimize, adapt and validate our whole system, and each one of its components and derived products to reach a TRL9. At the commercial level, we searched and identified many potential users and analyzed the advantages we can offer to them. We were also able to study different markets, compare our innovation with main competitors and describe BioCopy stakeholders, to evaluate the options we have to establish in the biopharma and animal vaccines markets as a highly competitive alternative. Financially, we could estimate the budget needed to reach commercialization and make projections on sells and profits after market launch.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Producing microarrays as BioCopy does would generate extremely high costs and times with current methods and in some cases it would be technologically impossible. None of the existing companies provides a similar tool for biomolecules copying and screening with the broad range of services and products we offer and with equivalent performance. Moreover, by using our system those companies can improve their processes and developmental pipelines and optimize results and costs. With our technology we can increase quantity and quality of biomolecules copied and analyzed by a minimum of 10-fold and significantly reduce costs.

Identification of vaccine candidates

Concept of the biomolecules copying

Company logo